Accessibility Menu
Krystal Biotech Stock Quote

Krystal Biotech (NASDAQ: KRYS)

$186.42
(-2.3%)
-4.36
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$186.42
Daily Change
(-2.3%) $4.36
Day's Range
$183.88 - $190.67
Previous Close
$186.42
Open
$190.67
Beta
1.33
Volume
265,200
Average Volume
350,875
Market Cap
5.4B
Market Cap / Employee
$186.42M
52wk Range
$122.8 - $207.84
Revenue
-
Gross Margin
0.92%
Dividend Yield
N/A
EPS
$4.92
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Krystal Biotech Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
KRYS+6.4%+287.17%+31.09%+1,693%
S&P+14.5%+93.32%+14.09%+167%

Krystal Biotech Company Info

Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$96.04M36.6%
Gross Profit$87.33M40.2%
Gross Margin90.93%2.3%
Market Cap$3.97B-24.3%
Market Cap / Employee$14.45M0.0%
Employees27520.1%
Net Income$38.33M146.2%
EBITDA$40.85M77.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$353.83M2.3%
Accounts Receivable$111.44M7.9%
Inventory31154.9%

Liabilities

Q2 2025YOY Change
Long Term Debt$8.06M27.5%
Short Term Debt$1.62M18.8%

Ratios

Q2 2025YOY Change
Return On Assets14.27%1.0%
Return On Invested Capital-7.63%3.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$50.83M1059.1%
Operating Free Cash Flow$52.73M1365.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings102.9852.4343.4227.96-44.37%
Price to Book6.235.095.494.03-38.45%
Price to Sales22.5416.1116.1511.38-65.23%
Price to Tangible Book Value6.235.095.494.03-38.45%
Price to Free Cash Flow TTM93.7539.2841.6522.05-
Enterprise Value to EBITDA133.5095.22126.3883.65-60.57%
Free Cash Flow Yield1.1%2.5%2.4%4.5%-
Return on Equity6.4%10.3%13.9%15.6%9.94%
Total Debt$7.48M$7.26M$9.66M$9.68M25.94%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.